ClinicalTrials.gg
RecruitingNCT07794891AURAUpdated Oct 8, 2026

Study to Assess Participant Satisfaction After Jawline and Neck Treatment

A Phase 4 interventional study of OnabotulinumtoxinA and SKINVIVE in Jawline and Neck Appearance, sponsored by AbbVie. Recruiting at 2 sites in Canada. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 8, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to evaluate overall participant satisfaction with the jawline and neck.

Participants will receive select Juvéderm products and onabotulinumtoxinA in the jaw area and neck per eligibility criteria.

The study will measure changes in psychological function, satisfaction with lower face and jawline and skin appearance. Participants will attend visits during the study at a clinical site. The effects of the treatment will be checked by medical assessments, vital signs, physical examinations, checking for side effects, and completing questionnaires.

02

Conditions studied

  • Jawline and Neck Appearance

Keywords

  • AURA Study
  • Jaw area and Neck Appearance
  • onabotulinumtoxinA
  • JUVÉDERM
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate or severe transverse neck lines based on investigator's live assessment
  • Moderate or severe loss of jawline definition based on investigator's live assessment.
  • Moderate or severe platysma prominence based on investigator's live assessment.

Exclusion criteria

Exclusion Criteria:

  • History of or current medical condition that may put the subject at increased medical risk with exposure to BOTOX, or any other condition that might interfere with neuromuscular function.
  • History of or current symptoms of dysphagia.
  • History of severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.
  • History of or allergy to any botulinum toxin serotype, Streptococcal or gram-positive bacterial proteins, lidocaine, HA products, any other or constituents of the study drug, device, and/or other products in the same class.
  • History of or tendency for keloid formation, hyperpigmentation, or hypertrophic scarring.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    JUVÉDERM Products Plus OnabotulinumtoxinA

    Participants in the study will receive the products in the jaw area, chin, and neck.

    Drug: OnabotulinumtoxinA · Device: SKINVIVE · Device: VOLUX · Device: VOLUMA

Interventions

  • Injection

  • DeviceSKINVIVE

    Injection

  • DeviceVOLUX

    Injection

  • DeviceVOLUMA

    Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response of Satisfied or Very Satisfied on Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction Follow-Up

    The ANLFQ is a 5-point scale that assesses participant satisfaction. Response options range from Very satisfied to Very dissatisfied.

    Time frame: Day 104

Secondary outcomes

  1. Change From Baseline in Participant's Rasch-transformed Score of the FACE-Q Psychological Function

    The FACE-Q Psychological Function scale assesses the psychological impact of facial appearance. The Rasch-transformed summary score ranges from worst to best.

    Time frame: Up to approximately 104 days

  2. Change From Baseline in Participant's Rasch-transformed Score of the FACE-Q Satisfaction With Lower Face and Jawline

    FACE-Q Satisfaction assesses participant satisfaction with the appearance of their lower face and jawline. The Rasch-transformed summary score ranges from worst to best.

    Time frame: Up to approximately 104 days

  3. Change From Baseline in Participant's Rasch-transformed Score of the SKIN-Q - Skin Looks

    SKIN-Q - Skin Looks assesses participant's satisfaction with how their skin looks. Rasch transformed scores ranges from worst to best.

    Time frame: Up to approximately 104 days

  4. Change From Baseline in Participant's Allergan Facial Confidence Scale (AFCS) - Confidence (Treatment Area) Total Score

    AFCS - Confidence (Treatment Area) is a questionnaire that assesses the participant's confidence in the appearance of the treatment area. 4-point response option ranges from Very Confident to Not at all confident.

    Time frame: Up to approximately 104 days

  5. Percentage of Participants With Response of Improved or Much Improved on Investigator Global Aesthetic Improvement Scale (GAIS)

    GAIS is a clinician-rated 5-point scale that assesses of overall aesthetic improvement compared to baseline. Scores range from "Much improved" to "Much worse".

    Time frame: Up to approximately 104 days

  6. Percentage of Participants With Response of Satisfied or Very Satisfied (or Agree or Definitely Agree) on Allergan Facial Satisfaction Scale (AFSS) - Natural Look and Feel

    AFSS assesses participant satisfaction. Scores range from "Very satisfied" to" Very dissatisfied".

    Time frame: Up to approximately 104 days

07

Study locations

2 of 2 sites recruiting
  • Humphrey & Beleznay Cosmetic Dermatology /ID# 282598
    Vancouver, British Columbia V5Z 4E1, Canada
    Recruiting
  • Sweat Clinics Of Canada /ID# 281845
    Toronto, Ontario M5R 3N8, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Aug 31, 2026
StartActual
Sep 9, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
2 sites added — first site in Canada
Show 2 added (2 Canada)
  • Humphrey & Beleznay Cosmetic Dermatology /ID# 282598 · Vancouver, Canada
  • Sweat Clinics Of Canada /ID# 281845 · Toronto, Canada
Oct 8, 2026
Start date
Sep 4, 2026→Sep 9, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Canada
    Show 2 added (2 Canada)
    • Humphrey & Beleznay Cosmetic Dermatology /ID# 282598 · Vancouver, Canada
    • Sweat Clinics Of Canada /ID# 281845 · Toronto, Canada
    Start date Sep 4, 2026→Sep 9, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07794891
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Sep 9, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion